22.445 CASOS INDIVIDUALES DE EFECTOS ADVERSOS CON ORIGEN EN ESPAÑA RECOGIDOS EN EUDRAVIGILANCE (8/02/2026) PARA COVID-19 VACCINE MODERNA (ELASOMERAN)
CASOS INDIVIDUALES EN EUDRAVIGILLANCE
PAÍSES
BLOOD AND LYMPHATIC SYSTEM DISORDERS
THROMBOCYTOPENIA
CARDIAC DISORDERS
MYOCARDITIS
EYE DISORDERS
This responds to your December 2, 2021, Freedom of Information Act (FOIA) request
addressed to the FOIA Office, National Institutes of Health (NIH). Department of Health
and Human Services’ (HHS) policy calls for the fullest possible disclosure provided by the
FOIA, 5 U.S.C. §552, consistent with the protections contained therein. The implementing
HHS Regulations establish the criteria pursuant to which the FOIA is administered, see 45
C.F.R. Part 5. Copies of the FOIA and the HHS FOIA Regulations are located at:
http://www.nih.gov/icd/od/foia/efoia.htm and http://www.nih.gov/icd/od/foia/cfr45.htm.
You requested All reports submitted by EcoHealth Alliance to NIH or its sub-agencies related to
NIH Grant No. 1R01AI110964 titled "Understanding the Risk of Bat Coronavirus Emergence"
during the term of the grant. (Date Range for Record Search: From 04/01/2014 To 12/02/2021).
NIH searched their files and found 552 pages of responsive records. The information being
withheld is protected from release pursuant to Exemptions 4 and 6 of the FOIA, 5 U.S.C. § 552
(b)(4) and (b)(6); and sections 5.31(d) and (f) of the HHS FOIA Regulations, 45 CFR Part 5.
Exemption 4 protects from disclosure trade secrets and commercial or financial information that
is privileged and confidential. Exemption 6 exempts from disclosure records the release of
which would cause a clearly unwarranted invasion of personal privacy.
You have the right to appeal this determination to deny you access to information in the
Agency’s possession. Should you wish to do so, your appeal must be sent within ninety (90) days
of the date of this letter, following the procedures outlined in Subpart F of the HHS FOIA
Regulations (https://www.federalregister.gov/documents/2016/10/28/2016-25684/freedom-ofinformation-regulations) to:
Records obtained by Judicial Watch show the National Institutes of Health funded an EcoHealth Alliance grant for sequencing the spike protein from coronaviruses obtained from bats to “creat[e] mutants to identify how significantly each would need to evolve to use ACE2,” which is explained as “the receptor to gain entry to human cells.”
Judicial Watch announced Wednesday it received 552 pages of records from the U.S. Department of Health and Human Services (HHS) that include the initial grant application and annual reports to the National Institutes of Health (NIH) from EcoHealth Alliance, describing the aim of its work with the Wuhan Institute of Virology (WIV) in China to create mutant viruses “to better predict the capacity of our CoVs [coronaviruses] to infect people.”
Eco Health Alliance planned to sequence the spike protein from coronaviruses obtained from bats for the purpose of “creating mutants to identify how significantly each would need to evolve to use ACE2,” which is explained as “the receptor to gain entry to human cells.”
Judicial Watch obtained the records through a Freedom of Information Act (FOIA) request it filed in December 2021 for:
“All reports submitted by EcoHealth Alliance to NIH or its sub-agencies related to NIH Grant No. 1R01A|110964 titled ‘Understanding the Risk of Bat Coronavirus Emergence” during the term of the grant.’”
In the initial “Application for Federal Assistance” submitted on June 5, 2013, by EcoHealth Alliance, a section is titled “Specific Aims,” which notes the intention to create mutant bat viruses and “predict the capacity of our CoVs [coronaviruses] to infect people”:
“To understand the risk of zoonotic CoV [coronavirus] emergence, we propose to examine 1) the transmission dynamics of bat-CoVs across the human-wildlife interface; and 2) how this process is affected by CoV evolutionary potential, and how it might force CoV evolution.
“We will assess the nature and frequency of contact among animals and people in two critical human-animal interfaces: live animal markets in China and people who are highly exposed to bats in rural China.”
“Specific Aim 3” discusses “Testing predictions of CoV inter-species transmission”:
“We will test our models of host range (i.e. emergence potential) experimentally using reverse genetics, pseudovirus and receptor binding assays, and virus infection experiments in cell culture and humanized mice.
“With bat-CoVs that we’ve isolated or sequenced, and using live virus or pseudovirus infection in cells of different origin or expressing different receptor molecules, we will assess potential for each isolated virus and those with receptor binding site sequence to spill over.
“We will do this by sequencing the spike (or other receptor binding/fusion) protein genes from all our bat-CoVs, creating mutants to identify how significantly each would need to evolve to use ACE2, CD26/DPP4 (MERS-CoV receptor) or other potential CoV receptors.”
In the continuing discussion of the aims of the research, the report states:
“In vitro [outside the body] cell lines & Humanized mouse model: We have developed primary cell lines and transformed cell lines from 9 bat species using kidney, spleen, heart, brain and intestine. We have used these for virus isolation, infection assays and receptor molecule gene cloning.
“We also have a large number of cell lines from humans and animals that we will use for virus infectivity assays. We have obtained a letter of support from Dr. Ralph Baric, who is keen to collaborate with us initially to infect his humanized mouse model with our bat SL-CoV [SARS-Like Coronavirus] that uses ACE2, and subsequently to use other CoVs that we identify …
“The results will provide information whether bat-CoVs could use known bat and human ACE2, DPP4 or other known CoV receptors to enter cells, and allow us to determine critical receptor binding sites, viral host range, and to better predict the capacity of our CoVs to infect people.”
EcoHealth Alliance’s $3.3 million grant to fund a project titled “Understanding the Risk of Coronavirus Emergence” was initially to run from Oct. 1, 2013, to Sept. 30, 2018. The first “Project/Performance Site Location” is the WIV.
Three other Chinese sites follow: East China Normal University in Shanghai, Yunnan Institute of Endemic Disease Control and Prevention in Dali and the Center for Disease Control and Prevention of Guangdong in Guangzhou.
On May 27, 2014, the NIH awarded EcoHealth Alliance $3,086,735 over five years for “Understanding the Risk of Bat Coronavirus Emergence.”
An EcoHealth Alliance grant application, received by the NIH on June 5, 2013, includes a list of “Senior/Key Personnel” including Shi Zhengli and Zhang Yun-Zhi of the WIV; Peter Daszak, CEO of EcoHealth Alliance; and other Chinese scientists, including Ke Changwen of the Chinese “CDC and Prevention of Guangdong Province.”
A section of the EcoHealth Alliance application titled “EcoHealth Alliance Budget Justification” describes some of the work to be conducted by EcoHealth scientists in China:
“A research scientist will be hired at 12 months time per year to provide direct assistance and oversight of field activities in China; maintain equipment and logistics; and coordinate animal and human sample shipment to the labs in China and in the US.
“Once we secure IRBs [Institutional Review Boards] for human sampling in Y1 [Year 1], we will hire three medical officers from China provincial CDCs [Centers for Disease Control] as consultants to work in Guangxi, Hunan, and Fujian during Y2-Y5. These medical officers will be responsible for IRB approved human sampling as well as maintaining cold chain for storage and shipping samples.
“Dr. Zhengli Shi, Senior Virologist. [Redacted] per year in Y1 -Y5. Dr. Shi will oversee the coronavirus screening for all samples collected in China. She will work with the PI [Principal Investigator], Co-Investigators, and Senior/Key Personnel to analyze data and write manuscripts. She will also coordinate data and material sharing with the co-investigators.”
In a budget calculation for the year 2014-15, the WIV as a sub-awardee of the grant was allocated to receive $128,718 in direct costs and $10,297 in indirect costs from NIH.
The salaries of Shi Zhengli and a WIV colleague Ge Xingyl are redacted from the budget. Over the five years of the grant, the Wuhan lab was to receive $749,976.
A section of the grant award titled “Wuhan Institute of Virology Budget Justification, Subaward” discusses “Other Direct Costs”:
We will be running RNA extractions for 1,000 bats per year (three samples per bat: oral, anal and blood) in each year … Extracted RNA per animal will be pooled.
In each year of the project, DNA sequencing will be performed on 3,200 samples at a cost of $2.91 per reaction. …
We request support for in vitro infection experiments using pseudoviruses carrying the spike proteins (wild type or mutants) or live viruses in cell lines of different origins, binding affinity assays between the spike proteins (wild types or mutants) and different cellular receptor molecules and humanized mouse experiments.
The Year 2 annual report for the bat coronavirus project, budget period June 1, 2016, to May 31, 2017, under “Specific Aim 3,” states:
“Testing predictions of CoV inter-species transmission. The following experiments will be undertaken in Year 2:
Among the “Additional Year 2 items for Specific Aim 3” are:
The annual report submitted for Year 3 of the grant project, budget period June 1, 2017, to May 31, 2018, under the heading “Specific Aim 3: Testing predictions of CoV inter-species transmission,” notes:
“In Year 3, we successfully isolated Rs4874 from the single [bat] fecal sample. Using the reverse genetic system we previously developed, we constructed two chimeric viruses with the WIV1 backbone replaced with the S [spike] gene of Rs7327 and Rs4231, respectively.
“Vero E6 cells were respectively infected with Rs4874, WIV1-Rs4231S and WIV1-Rs7327S, and efficient virus replication was detected by immunofluorescence assay in all infections.
“To assess the usage of human ACE2 by the three novel SL-CoVs, we conducted virus infectivity studies using HeLa cells with or without the expression of human ACE2. All viruses replicated efficiently in the human ACE2-expressing cells.”
In the Year 4 annual report, budget period June 1, 2018, to May 31, 2019, submitted to NIH by EcoHealth on Sept. 16, 2020, in answer to the question “How Have the Results Been Disseminated to Communities of Interest,” the report details that Peter Daszak and WIV lab director Shi Zhengli briefed their findings to, among others, the Defense Advanced Research Projects Agency, the National Natural Science Foundation of China, the Chinese Center for Disease Control and Prevention and the Chinese Academy of Sciences.
Among the accomplishments listed in the Year 4 report is:
“In vivo [experimentation done in a whole organism] infection of SARSr-CoVs with variants of S [spike] protein in human ACE2 (hACE2) expressing mice.”
The report also includes information about the construction of viruses of “varying pathogenicity” and testing them on humanized mice:
“Using the reverse genetic methods we previously developed, infectious clones with the WIV1 [bat SARS-like coronavirus] backbone and the spike protein of SHC014, W IV16 and Rs4231, respectively, were constructed and recombinant viruses were successfully rescued.
“In Year 4, we performed preliminary in vivo infection of SARSr-CoVs on transgenic mice that express hACE2. Mice were infected with 105 pfu of full-length recombinant virus of W IV1 (rWIV1) and the three chimeric viruses with different spikes.
“Pathogenesis of the 4 SARSr-CoVs was then determined in a 2-week course. Mice challenged with rWIV1-SHC014S have experienced about 20% body weight loss by the 6th day post infection, while rWIV1 and rWIV-4231 S produced less body weight loss.
“In the mice infected with rWIV1 -WIV16S, no body weight loss was observed (Fig. 35a). 2 and 4 days post infection, the viral load in lung tissues of mice challenged with rWIV1-SHC014S, rWIV1-WIV16S and rWIV1-Rs4231 S reached more than 106 genome copies/g and were significantly higher than that in rWIV1-infected mice (Fig. 35b). These results demonstrate varying pathogenicity of SARSr-CoVs with different spike proteins in humanized mice.”
In a revised award dated July 13, 2020, the NIH granted additional funds, including $77,750 to the University of North Carolina-Chapel Hill, $76,301 to the WIV and $75,600 to the Institute of Pathogen Biology of China.
The 2020 renewal application to extend funding for the Wuhan bat research projects states that EcoHealth would not be working with “select agents” (severe threats), such as SARS-CoV, but rather with a SARSr-CoV molecular clone designated WIV1 which, while a “BSL3” (biosafety level 3) pathogen, was not considered a select agent.
The select agent research was to be conducted at Baric’s lab at the University of North Carolina-Chapel Hill.
A section titled “P3CO Research” notes:
“Importantly, we are not proposing to genetically manipulate SARS-CoV over the course of this proposal. … However, we are proposing to genetically manipulate the full length bat SARSr-CoV WIV1 strain molecular clone during the course of this proposal, which is not a select agent, has not been shown to cause human infections, and has not been shown to be transmissible between humans.”
The same 2020 renewal application states:
“This project is a multi-institutional collaboration led by EcoHealth Alliance, New York (Daszak, PI), which will subcontract funds to three institutions: the Wuhan Institute of Virology (Dr. Shi), the University of North Carolina at Chapel Hill (Dr. Baric), and the Institute of Pathogen Biology (Dr. Ren).”
“A review of these and other documents strongly suggest that U.S. funding in China and elsewhere for mutant virus, gain-of-function research may have been responsible for the emergence of the COVID pandemic in Wuhan,” said Judicial Watch President Tom Fitton.
“This gain-of-function scandal should be the subject of criminal investigations.”
Through FOIA, Judicial Watch has uncovered a substantial amount of information about COVID-19 issues:
Take a look at page 127:
The above page describes “receptor mutants and pseudoviruses,” specifically a mutant of HIV backbone with SARS-like “spike proteins.” These NIH-funded researchers created these HIV-SARS mutants to see how well they would infect human lungs and experimented on “humanized mice” whose lung cells resembled human cells.
These mutant viruses are, in a way, the opposite of Sars-Cov-2. They represent an HIV backbone with SARS-like spike protein.
Sars-Cov-2, on the contrary, is a coronavirus backbone with spike-protein carrying HIV genes. (Such a chimera is described in the DEFUSE proposal submitted by Peter Daszak to another government agency)
HIV is an exceptionally cunning virus: it integrates into the human DNA after infection. Such integration is called “reverse transcription,” whereby RNA from the virus becomes part of the DNA of human cells. HIV essentially edits the human genome and inserts its code into it. After that, human cells produce new HIV viral particles, as this NIH page explains.
 |
However, HIV is not very contagious. It cannot target cellular receptors found in human lungs, for example. One cannot get HIV via the airborne route: HIV infections require blood-to-blood transmission, and HIV-carrying aerosols cannot infect human respiratory systems.
A pseudovirus that can infect human ACE2 cells, which are present in our lungs, is one step closer to airborne transmission: an aerosol carrying ACE-2-infecting HIV mutant could infect someone upon being breathed in.
Is the research that creates ACE-2-infecting HIV mutants, which may be contagious via the respiratory route, safe? What if these recombinants escape the laboratory?
And yet, in search of grant money, fame, and discoveries, virologists funded by the NIH conducted such experiments involving ACE2-infecting HIV chimeras with minimal oversight.
Their work gave us Sars-CoV-2 and the Covid pandemic. Again, Sars-Cov-2, a recombinant chimera carrying HIV genes on a coronavirus backbone, is NOT the same as the pseudovirus described above; it is something else but related.
The above shows that work on HIV/SARS coronavirus recombinants, funded by the NIH, was conducted by the same people whose cooperation with the Wuhan Institute of Virology gave us the Covid pandemic.
Almost every human was infected with the HIV-gene-carrying COVID virus. Every COVID-vaccinated human was injected with spike-protein-producing mRNA, which encoded the same HIV genes.
Numerous fact-checking articles attempted to deny the link between HIV and Sars-Cov-2.
 |
 |
Those assurances are false.
The document I highlighted shows evidence that the same people who gave us Sars-Cov-2 also worked on HIV/SARS chimeras. Therefore, there is a “plausible route” by which the Covid pandemic virus could carry HIV genes. This belies the fact-checkers’ hollow claims.
Casi todos los humanos han sido infectados con el #virus #COVID que porta #genes del #virus del #SIDA. Casi todos los humanos han sido vacunados con la "spike protein" que produce #mRNA que codifica los mismos #genes del #virus del #SIDA
— Guillermo Ruiz Zapatero (@ruiz_zapatero) April 23, 2023
ASÍ CONSTA EN LOS DOCUMENTOS FOIA https://t.co/Wbd54UZWLu
Where is CTCCTCGGCGGGCACGTAG in the Moderna Patent
Igor Chudov
Two astute readers asked me a very reasonable question: where in the Moderna patent 9,587,003, exactly, is something that matches the Sars-Cov-2 sequence CTCCTCGGCGGGCACGTAG? I am trying to explain here. We get: CTACGTGCCCGCCGAGGAG in the Moderna patent sequence 11652.
Go to the “Reverse Complement Calculator”: https://bugaco.com/calculators/dna_reverse_complement.php
Now type in the genes from Sars-Cov-2 (which is CTCCTCGGCGGGCACGTAG):
So, this shows that the Sars-Cov-2 sequence CTCCTCGGCGGGCACGTAG, matches the Moderna patent sequence CTACGTGCCCGCCGAGGAG as a “reverse complement”.
This is the explanation of “reverse complement”.
Remember that Sars-Cov-2 is a RNA virus and Moderna patents are DNA
(DNA STRUCTURE AND THE REVERSE COMPLEMENT OPERATION)
None of this tells us whether this sequence is “good”, “bad”, “pure chance”, etc.
All we know is: CTCCTCGGCGGGCACGTAG is the most crucial part of Sars-Cov-2 RNA, containing the code for the “furin cleavage site”
No natural coronaviruses contain a “furin cleavage site”
Furin cleavage site greatly enhances infectivity of Sars-Cov-2 and its ability to infect humans and other species
This code only appears in a Moderna oncology (cancer) patent 9587003, and not in any multicellular organisms or viruses known before 2020
The mutation of MSH3 gene related to this patent, is known to break DNA recombination and lead to cancers (see my previous article)
Spike protein is also known to penetrate cell nuclei and interfere with V(D)J DNA recombination and BRCA1 and p53 repair, for a reason that MAY OR MAY NOT be related to CTCCTCGGCGGGCACGTAG
BRCA mutation is responsible for breast and ovarian cancer
https://thoreaucastellano.blogspot.com/2022/02/where-is-ctcctcggcgggcacgtag-in-moderna_24.html
#covid19
#modernavaccine
#JAPAN
Japan suspends Moderna Covid vaccine after another million doses found contaminated, bringing total to 2.6 million
Japanese officials have suspended the use of millions of doses of the Moderna Covid vaccine after foreign substances were found in a number of batches and two people died after receiving jabs from the affected lots.
The Japanese government discovered the contamination over the weekend in a batch of the Moderna Covid vaccine in Gunma prefecture, close to Tokyo, forcing officials to temporarily suspend use of the vaccines.
The decision to suspend a total of 2.6 million doses of the Moderna vaccines comes after 1.63 million shots were halted last week following the discovery of contaminants in some vials in a batch that was shipped to more than 860 vaccination centers across the country.
While the source of the contamination has not been confirmed, Moderna and pharmaceutical company Rovi, which manufactures the Moderna vaccines, said that it could be due to a manufacturing fault on one of the production lines, rather than anything more concerning.
30 Aug, 2021 10:41
https://www.rt.com/news/533431-japan-suspends-moderna-vaccine-contaminated/
